Barclays lowered the firm’s price target on Cellectis (CLLS) to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks